Silverback Therapeutics Inc

NASDAQ SPRY

Data sourced from

and

Download Data

Silverback Therapeutics Inc Capital Expenditures for the year ending December 31, 2023: USD -175.00 K

Silverback Therapeutics Inc Capital Expenditures is USD -175.00 K for the year ending December 31, 2023, a 12.06% change year over year. Capital Expenditures represent the amount of money spent on acquiring or improving long-term assets, such as property, plant, and equipment.

Silverback Therapeutics Inc Capital Expenditures for the year ending December 31, 2022 was USD -199.00 K, a -261.82% change year over year.
Silverback Therapeutics Inc Capital Expenditures for the year ending December 31, 2021 was USD -55.00 K, a 94.00% change year over year.
Silverback Therapeutics Inc Capital Expenditures for the year ending December 31, 2020 was USD -917.00 K.

NASDAQ: SPRY

Silverback Therapeutics Inc

CEO	Mr. Richard Lowenthal M.B.A., M.S., MSMSEL
IPO Date	Dec. 4, 2020
Location	United States
Headquarters	3525 Del Mar Heights Road, San Diego, CA, United States, 92130
Employees	24
Sector	Healthcare
Industry	Biotechnology

Description

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Key trends